A Canadian banking firm has kicked off its coverage of the US cannabis space by selecting its first multi-state operator (MSO) securities to cover.

The US growth seen from investments in the US cannabis market players has led to a flock of investor attention to south of the border. As such, Echelon Wealth Partners has moved forward with the launch of its coverage for this sector.

The financial institution began its analysis of the alluring sector and assigned some targets for a selection of companies.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

Using a projection of the average cannabis user rate across the whole country — with the average spending currently seen — Echelon Wealth forecasted the US cannabis market to be worth US$60 billion.

Echelon Wealth assigned positive ratings to Columbia Care (NEO:CCHW,OTCQX:CCHWF), Cresco Labs (CSE:CL,OTCQX:CRLBF) and Green Thumb Industries (GTI) (CSE:GTII,OTCQX:GTBIF) on August 12.

The institution assigned a “buy” recommendation to GTI, while Columbia Care and Cresco Labs each earned a “speculative buy” rating.

The research note designated one-year price ratings of C$24, C$11.50 and C$15 respectively for the MSOs.

Matthew Pallotta, equity research analyst at Echelon Wealth Partners, is the analyst assigned by the firm to cover these companies.Pallotta joined Echelon Wealth in March, but has been covering cannabis stocks for over three years now.

In an exclusive interview with the Investing News Network (INN), Pallotta revealed some of the trends he is seeing in this space.

When asked which markets in the US piqued his interest the most right now, Pallotta highlighted Florida, New York, Nevada and Illinois as the states at the top of his watch list.

Despite the federal illegality of marijuana in the US, the industry has flourished thanks to the opening of markets by way of state-level programs protected from federal prosecution.

A sweeping marijuana legalization effort from the federal powers in the US has been suggested, but doesn’t seem likely anytime soon.

The analyst explained — in his view — how MSOs are trading at a discount compared to the Canadian companies dominating the marijuana stock market.

While many experts agree on the premium seen between Canadian and US names, Pallotta expects to see that gap close down even before the development of crucial policies in the US.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

“I think the discount is probably going to close regardless once people start seeing the revenue numbers these businesses are putting up,” Pallotta told INN.

However, despite this prediction, Pallotta is anticipating the passing of bills — such as the STATES Act — will represent the boom for MSOs. The STATES Act is a proposed federal bill that would permit the states to decide how to openly operate cannabis programs throughout the country.

When it comes to the disparity between US-based cannabis MSOs and the Canadian leaders, which have seen an early lead to senior US exchanges — something still unavailable to MSOs due to the federal illegality of the drug — Pallotta said the business fundamentals of MSOs is strong enough to help close the difference.

Despite these projections, Pallotta is not discounting the Canadian names known to marijuana investors due to the support thrown to Canadian companies by institutional investors looking for legal marijuana exposure.

“There’s institutional money that, because of those rules and whether they like the US players or not, won’t be able to go in,” he said.

The interest in MSOs has risen enough in 2019 to justify the launch of two exchange-traded funds (ETFs) in Canada dedicated entirely to the US cannabis space.

“Clearly we are moving now in a period where there was a lot of focus on US marijuana firms,” Jos Schmitt, president and CEO of the Toronto-based NEO Exchange, told INN. “There’s a lot of interest in that space.”

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

A middling Canadian cannabis producer announced an executive turnover plan this week after receiving a critical investor letter in September.

Meanwhile, a Canadian exchange-traded fund (ETF) company released lists of new additions to both of its cannabis funds as part of its quarterly rebalancing.

Keep reading... Show less
  • The Cannabis Derivatives are derived from Avicanna’s cultivation and extraction infrastructure in Santa Marta, Colombia designed to supply partner companies and the manufacture of Avicanna’s own finished products.

Avicanna Inc. (” Avicanna ” or the ” Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that, through its majority owned Colombian subsidiary, Santa Marta Golden Hemp S.A.S. (“ SMGH ”), it has completed a commercial exports of CBD Isolate and CBD full spectrum psychoactive cannabis resin (the “ Cannabis Derivatives ”) to a leading Chilean homeopathic and naturopathic pharmaceutical company.

The Cannabis Derivatives, branded as Aureus™, are cultivated, extracted, and manufactured by SMGH. In addition, for Avicanna’s global input needs, SMGH also supplies other pharmaceutical and cosmetics companies with cannabinoids including CBD, THC, and rare cannabinoids such as CBG in addition to supplying global cultivation companies with standardized and feminized seeds. This new export to Chile is a recurring order and part of on-going relationship with an established homeopathic Chilean company.

Keep reading... Show less

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX:WEED, NASDAQ:CGC) will release its financial results for the second quarter fiscal year 2022 ended September 30, 2021 before financial markets open on November 5, 2021 .

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco Labs” or “the Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, announced today the opening of a new Sunnyside dispensary in Wyomissing, Pennsylvania. Wyomissing will be Cresco Labs’ fifth dispensary in Pennsylvania and 38 th nationwide.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211021006075/en/

Keep reading... Show less

The world of cannabis consumption is set to change radically, thanks in large part to the advancement of state-of-the-art research on the plant itself.

Medical cannabis products have already allowed many new users to discover the plant’s potential, but decisive research will help build a foundation for more sophisticated medical offerings.

Keep reading... Show less